ClassID:

96701

C07K5/06165 - CPC Classification

Classification description:

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Recent Application in this class:
#1
20250320195
2025-10-16

TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

#2
20240201189
2024-06-20

FLUORESCENT PROBE FOR USE IN DETECTION OF PANCREATIC CANCER

#3
20240076281
2024-03-07

TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

#4
20240059686
2024-02-22

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR

#5
20230390408
2023-12-07

LINKER COMPOUNDS COMPRISING AMIDE BONDS

#6
20230374112
2023-11-23

Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof

#7
20230312644
2023-10-05

COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING

#8
20230133465
2023-05-04

Compositions and methods for treating and preventing neurodegenerative disorders

#9
20220388984
2022-12-08

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

#10
20220274955
2022-09-01

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

#11
20220167610
2022-06-02

DMSO-FREE CRYOPRESERVATION SOLUTION AND PREPARATION METHOD AND USE THEREOF

#12
20220144909
2022-05-12

CSF1R-BASED CHIMERIC PROTEINS

#13
20220073499
2022-03-10

Functionalized peptides as antiviral agents

#14
20220041652
2022-02-10

FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS

#15
20210355163
2021-11-18

COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING

#16
20210139458
2021-05-13

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

#17
20210047367
2021-02-18

Preparation and uses of reactive oxygen species scavenger derivatives

#18
20200347012
2020-11-05

Compositions and methods for treating and preventing neurodegenerative disorders

#19
20200253852
2020-08-13

Pro-pigmenting peptides

#20
20200237637
2020-07-30

N-acyldipeptide derivatives and their uses

#21
20200181194
2020-06-11

Preparation and uses of reactive oxygen species scavenger derivatives

#22
20200123214
2020-04-23

CSF1R-based chimeric proteins

#23
20200055895
2020-02-20

COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING

#24
20190382466
2019-12-19

CSF1R-CD40L chimeric proteins

#25
20190309014
2019-10-10

PROCESS FOR PREPARATION OF ICATIBANT ACETATE

#26
20190169249
2019-06-06

CSF1R-based chimeric proteins

#27
20190161467
2019-05-30

N-lipoic-amino acid or peptide, derivatives and their uses

#28
20190142723
2019-05-16

Pro-pigmenting peptides

#29
20190135862
2019-05-09

NDMA RECEPTOR MODULATORS AND USES THEREOF

#30
20190085024
2019-03-21

Alpha-Ketoamide Inhibitors Of Cysteine Proteases

#31
20190083631
2019-03-21

Carbonic anhydrase IX inhibitor conjugates and uses thereof

#32
20180346780
2018-12-06

Molecular gelators and uses thereof

#33
20180346461
2018-12-06

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

#34
20180312636
2018-11-01

Method for manufacturing a metal nanostructure having a chiral structure comprising regioselectivity adsorbing a peptide on the surface of a metal seed particle

#35
20180303741
2018-10-25

Combination of N-acyldipeptide derivatives and retinol, and methods of use thereof

#36
20180237474
2018-08-23

NMDA RECEPTOR MODULATORS AND USES THEREOF

#37
20180170961
2018-06-21

Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient

#38
20180155322
2018-06-07

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

#39
20180134748
2018-05-17

Process for preparing compounds having triple activities of thrombolysis, antithrombosis, and radical scavenging

#40
20180127463
2018-05-10

Desacetoxytubulysin H and analogs thereof

#41
20170260232
2017-09-14

TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE

#42
20170239365
2017-08-24

Pyrrolobenzodiazepines and conjugates thereof

#43
20170224759
2017-08-10

Compositions and methods for treating colorectal cancer

#44
20170119646
2017-05-04

N-acyldipeptide derivatives and their uses

#45
20170071844
2017-03-16

Pro-pigmenting peptides

#46
20170035858
2017-02-09

Myoblast differentiation promoter

#47
20170008922
2017-01-12

Branched chain-containing aromatic compound

#48
20160355547
2016-12-08

Dimeric IAP inhibitors

#49
20160264624
2016-09-15

Tubulysin compounds, methods of making and use

#50
20160243249
2016-08-25

HCV protease inhibitors and uses thereof

#51
20160214972
2016-07-28

Compounds and methods for the targeted degradation of androgen receptor

#52
20160083423
2016-03-24

Compounds having triple activities of thrombolysis, antithrombosis, and radical scavenging, synthesis, and use thereof

#53
20160082069
2016-03-24

4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

#54
20160052965
2016-02-25

Dimeric IAP Inhibitors

#55
20150315234
2015-11-05

MYOBLAST DIFFERENTIATION PROMOTER

#56
20150299254
2015-10-22

Polymers, pharmaceutical compositions and methods of synthesizing the same

#57
20150274776
2015-10-01

Pro-pigmenting peptides

#58
20150250846
2015-09-10

N-acyldipeptide derivatives and their uses

#59
20150232509
2015-08-20

SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS

#60
20150232504
2015-08-20

Aldehyde capture ligation technology for synthesis of amide bonds

#61
20150175657
2015-06-25

HCV protease inhibitors and uses thereof

#62
20150175654
2015-06-25

Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient

#63
20150166600
2015-06-18

Acyl dipeptide derivative

#64
20150158869
2015-06-11

Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates

#65
20150132324
2015-05-14

Tubulysin compounds, methods of making and use

#66
20150087600
2015-03-26

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

#67
20150037268
2015-02-05

Niacin-peptide having skin whitening activity and use for same

#68
20150031627
2015-01-29

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

#69
20140357551
2014-12-04

Organic compounds and their uses

#70
20140328796
2014-11-06

4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

#71
20140323465
2014-10-30

HCV protease inhibitors and uses thereof

#72
20140309401
2014-10-16

DPP-4 inhibitor

#73
20140303080
2014-10-09

N-acyldipeptide derivatives and their uses

#74
20140275520
2014-09-18

Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof

#75
20140227298
2014-08-14

Tubulysin compounds, methods of making and use

#76
20140227295
2014-08-14

Tubulysin compounds, methods of making and use

#77
20140018300
2014-01-16

Neuroprotective and neurorestorative methods and compositions

#78
20130338076
2013-12-19

Peptides and methods using same for diagnosis and treatment of amyloid-associated disease

#79
20130338062
2013-12-19

HCV protease inhibitors and uses thereof

#80
20130310311
2013-11-21

Selective inhibitors of prolylcarboxypeptidase

#81
20130178630
2013-07-11

Process for making HCV protease inhibitors

#82
20130071352
2013-03-21

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

#83
20130035292
2013-02-07

NMDA receptors modulators and uses thereof

#84
20130034519
2013-02-07

Peptidomimetic sulfamide compounds and antiviral uses thereof

#85
20130022572
2013-01-24

Peptidomimetic sulfamide compounds and antiviral uses thereof

#86
20130017991
2013-01-17

HCV protease inhibitors and uses thereof

#87
20120309938
2012-12-06

Hemiasterlin derivatives and uses thereof in the treatment of cancer

#88
20120258919
2012-10-11

Collagen peptide, dipeptide and malady inhibitor

#89
20120253011
2012-10-04

Native chemical ligation at serine and threonine sites

#90
20120231998
2012-09-13

Organic compounds and their uses

#91
20120190614
2012-07-26

HCV protease inhibitors and uses thereof

#92
20120059149
2012-03-08

Branched chain-containing aromatic compound

#93
20120040055
2012-02-16

COLLAGEN PEPTIDE COMPOSITION HAVING GOOD ABILITY TO ENTER THE BLOOD AND FOOD OR BEVERAGE CONTAINING THE SAME

#94
20120027781
2012-02-02

Neuroprotective and neurorestorative method and compositions

#95
20110312890
2011-12-22

ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS

#96
20110301151
2011-12-08

Dimeric IAP inhibitors

#97
20110294719
2011-12-01

Dipeptoid prodrugs and the use thereof

#98
20110275713
2011-11-10

Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements

#99
20110230419
2011-09-22

IAP BINDING COMPOUNDS

#100
20110177055
2011-07-21

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

#101
20110171690
2011-07-14

Angiotensin converting enzyme inhibitory peptide

#102
20110166365
2011-07-07

Collagen peptide, dipeptide and malady inhibitor

#103
20110150827
2011-06-23

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

#104
20110070168
2011-03-24

Macrocyclic peptides as inhibitors of viral replication

#105
20100331243
2010-12-30

Organic compounds and their uses

#106
20100260709
2010-10-14

Derivatised proline containing peptide compounds as protease inhibitors

#107
20100240698
2010-09-23

Macrocyclic inhibitors of hepatitis C virus

#108
20100197609
2010-08-05

Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs

#109
20100179119
2010-07-15

Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold

#110
20100173939
2010-07-08

ANTIVIRAL COMPOUNDS

#111
20100152103
2010-06-17

4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication

#112
20100113440
2010-05-06

Pyrimidine substituted macrocyclic HCV inhibitors

#113
20100105608
2010-04-29

Peptides and methods using same for diagnosis and treatment of amyloid-associated disease

#114
20100075911
2010-03-25

Dimeric IAP inhibitors

#115
20100069294
2010-03-18

HCV protease inhibitors and uses thereof

#116
20100063095
2010-03-11

Hemiasterlin derivatives and uses thereof in the treatment of cancer

#117
20100056432
2010-03-04

TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY

#118
20100047841
2010-02-25

SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF

#119
20100041674
2010-02-18

HCV protease inhibitors and uses thereof

#120
20100041591
2010-02-18

HCV protease inhibitors and uses thereof

#121
20100022459
2010-01-28

Peptides directed for diagnosis and treatment of amyloid-associated diseases

#122
20090306085
2009-12-10

HCV protease inhibitors and uses thereof

#123
20090286763
2009-11-19

AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF

#124
20090233968
2009-09-17

Inhibitors of the α2β1/GPIa-IIa integrin

#125
20090215093
2009-08-27

COMPOUNDS FOR ENZYME INHIBITION

#126
20090197861
2009-08-06

Inhibitors of integrin alpha2beta1 with modified urea moiety

#127
20090191151
2009-07-30

Triazole-containing macrocyclic HCV serine protease inhibitors

#128
20090180984
2009-07-16

Macrocyclic oximyl hepatitis C serine protease inhibitors

#129
20090180983
2009-07-16

Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease

#130
20090180981
2009-07-16

Quinoxalinyl derivatives

#131
20090176858
2009-07-09

HCV protease inhibitors and uses thereof

#132
20090175822
2009-07-09

C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors

#133
20090093639
2009-04-09

Prodrugs of carbamate inhibitors of IMPDH

#134
20090082261
2009-03-26

Urea-containing peptides as inhibitors of viral replication

#135
20090048297
2009-02-19

4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

#136
20080292587
2008-11-27

OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS

#137
20080287449
2008-11-20

AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS

#138
20080267918
2008-10-30

Quinoxalinyl dipeptide hepatitis C virus inhibitors

#139
20080200511
2008-08-21

Amino acid derivatives and pharmaceutical uses thereof

#140
20080200503
2008-08-21

Macrocyclic inhibitors of hepatitis C virus

#141
20080177029
2008-07-24

Process for preparing macrocyclic compounds

#142
20080146524
2008-06-19

Selective inhibitors of neurotensin degrading enzymes

#143
20080051434
2008-02-28

Hemiasterlin derivatives and uses thereof in the treatment of cancer

#144
20070286842
2007-12-13

Organic compounds and their uses

#145
20070276002
2007-11-29

Compounds and compositions as channel activating protease inhibitors

#146
20070265281
2007-11-15

Organic Compounds and Their Uses

#147
20070235275
2007-10-11

Multi-location tractor trailer pneumatic connections

#148
20070112060
2007-05-17

Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements

#149
20070066533
2007-03-22

Cell adhesion inhibitors

#150
20070037863
2007-02-15

Dipeptide phenyl ethers

#151
20070021345
2007-01-25

Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

#152
20070021330
2007-01-25

Aza-peptide macrocyclic hepatitis c serine protease inhibitors

#153
20070004646
2007-01-04

Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

#154
20060234947
2006-10-19

Peptides directed for diagnosis and treatment of amyloid-associated disease

#155
20060194741
2006-08-31

Dimeric IAP inhibitors

#156
20060166961
2006-07-27

Cell adhesion inhibitors

#157
20060166893
2006-07-27

2-hydroxytetrahydrofuran derivatives and use thereof as medicaments

#158
20060134604
2006-06-22

Flexible method and apparatus for high throughput production and purification of multiple proteins

#159
20060100160
2006-05-11

Amino acid derived prodrugs of propofol, compositions and uses thereof

#160
20060088471
2006-04-27

Compounds for enzyme inhibition

#161
20060069238
2006-03-30

Synthetic glyco-lipo-peptides as vaccines

#162
20060014966
2006-01-19

Cell adhesion inhibitors

#163
20060014701
2006-01-19

Novel amide derivatives as growth hormone secretagogues

#164
20050272668
2005-12-08

Anti-inflammatory compositions and methods

#165
20050239870
2005-10-27

Hemiasterlin derivatives and uses thereof

#166
20050239693
2005-10-27

Template-fixed peptidomimetics with antibacterial activity

#167
20050222395
2005-10-06

New peptide derivatives

#168
20050222119
2005-10-06

Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4

#169
20050222045
2005-10-06

Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments

#170
20050209135
2005-09-22

Process for preparing macrocyclic compounds

#171
20050143391
2005-06-30

Heterocyclic amides with alpha-4 integrin antagonist activity

#172
20050124597
2005-06-09

Novel guanidinyl derivatives

#173
20050101664
2005-05-12

Prodrugs of carbamate inhibitors of IMPDH

#174
20050075293
2005-04-07

Dipeptide phenyl ethers

#175
20050075280
2005-04-07

Antiarrhythmic peptides

#176
20050065073
2005-03-24

Aza-peptide macrocyclic hepatitis C serine protease inhibitors

#177
20050049406
2005-03-03

Isotopically coded affinity markers 3

#178
20050020809
2005-01-27

Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

#179
20050004100
2005-01-06

ACE inhibitor derivatives